Facing a silent threat? Chronic kidney disease (CKD) is quietly becoming a major health crisis in the United States, impacting millions. Shockingly, an estimated 36 million adults are currently living with this condition, often without even realizing it. But, researchers are working tirelessly to change this.
Dr. Alejandro Chade and his team at the University of Missouri School of Medicine and NextGen Precision Health Building are diving deep into the complexities of CKD, searching for new and improved treatments. Their goal? To identify potential therapeutic targets that could slow the progression of this devastating disease and improve the lives of those affected.
The challenge is significant. CKD is a progressive disease, meaning it worsens over time. Early on, many people show no symptoms, and as many as 9 out of 10 adults are unaware they have the disease. By the time it's diagnosed, the kidneys may be severely damaged, potentially requiring dialysis or a kidney transplant. Imagine the impact of delaying or even preventing these drastic measures!
In CKD, the kidneys, which are responsible for filtering waste from the blood, become damaged. This damage leads to a cascade of problems, including loss of small blood vessels, inflammation, and fibrosis (excessive scar tissue).
But here's where it gets interesting: Dr. Chade's research, using animal models, has pinpointed several genes that could be key targets for therapy. By analyzing protein and cell interactions, the team discovered that silencing certain genes, for example, led to reduced fibrotic activity. This suggests these genes play a crucial role in kidney function and the development of CKD.
"We identified genes that seem involved with the signs of kidney damage," Dr. Chade explained. "Some genes had higher activity in CKD models, and others were involved in the communication pathways that enable inflammation, fibrosis or the growth of new blood vessels."
And this is the part most people miss... The next step is to understand where else these genes are active in the body and what happens when their activity is modified. This is critical to ensure any new treatments don't have unintended side effects.
Dr. Chade emphasizes that new therapies for CKD could prevent or postpone the need for dialysis or transplantation, ultimately preserving patients' health and quality of life.
Dr. Alejandro R. Chade, a professor at the Mizzou School of Medicine and a NextGen Precision Health Investigator, led this groundbreaking research. The findings were recently published in Kidney360, an official journal of the American Society of Nephrology. The research team also included data scientist Sathesh Sivasankaran, research specialists Rhys Sitz and Elizabeth McCarthy, and Dr. Alfonso Eirin from the Mayo Clinic.
What do you think? Are you surprised by the prevalence of CKD? Do you believe that identifying specific gene targets offers the most promising path toward effective treatments? Share your thoughts in the comments below!
